Managed Healthcare Executive September 3, 2024
Cell and gene therapies are becoming almost an everyday clinical reality. But the price tags? They still have shock value. Payers and providers are working out single-case agreements ahead of when the therapies are given.
Familiar drugs such as Humira (adalimumab) and Stelara (ustekinumab) still top the list when it comes to drug costs. The glucagon-like peptide-1 agonists such as semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, have joined their ranks.
But now many ultraexpensive cell and gene therapies are in late-stage development, and a number of them are on the brink of FDA approval. Healthcare systems and payers are bracing themselves for an era when cell and gene therapy will be an everyday clinical reality...
Today's Sponsors
Today's Sponsor